Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CMI-392 is a dual 5-lipoxygenase inhibitor and platelet-activating factor (PAF) receptor antagonist (IC50s: 100 and 10 nM).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 8-10 weeks | $ 2,120.00 | |
50 mg | 8-10 weeks | $ 2,780.00 | |
100 mg | 8-10 weeks | $ 3,700.00 |
Description | CMI-392 is a dual 5-lipoxygenase inhibitor and platelet-activating factor (PAF) receptor antagonist (IC50s: 100 and 10 nM). |
Targets&IC50 | PAF:10 nM, 5-LOX:100 nM |
In vivo | In the acute and chronic TPA models, topical treatment with CMI-392 results in a significant decrease of ear weight, inflammatory cell infiltration, and histological examination. The ED50 for PAF-induced mouse hemoconcentration and arachidonic acid-induced mouse ear edema are 2.2 and 1.8 mg/kg, respectively. |
Molecular Weight | 633.15 |
Formula | C31H37ClN2O8S |
CAS No. | 205654-37-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
CMI-392 205654-37-1 Others CMI 392 CMI392 inhibitor inhibit